Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
27.21
-1.19 (-4.19%)
Jul 24, 2026, 2:07 PM EDT - Market open
Pelthos Therapeutics Revenue
Pelthos Therapeutics had revenue of $10.91M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $27.70M. In the year 2025, Pelthos Therapeutics had annual revenue of $16.80M.
Revenue (ttm)
$27.70M
Revenue Growth
n/a
P/S Ratio
3.43
Revenue / Employee
$301,098
Employees
92
Market Cap
94.57M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.80M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| Verrica Pharmaceuticals | 37.16M |
| ImmuCell | 29.93M |
| Coya Therapeutics | 7.94M |
| Entera Bio | 42.00K |
| NeOnc Technologies Holdings | 39.99K |
PTHS News
- 23 days ago - Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes - GlobeNewsWire
- 2 months ago - Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Pelthos Therapeutics price target raised to $66 from $62 at Oppenheimer - TheFly
- 2 months ago - Pelthos Therapeutics reports Q1 EPS ($3.58), consensus ($3.09) - TheFly
- 2 months ago - Pelthos Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 2 months ago - Pelthos Therapeutics Earnings release: Q1 2026 - Filings
- 2 months ago - Pelthos Therapeutics Quarterly report: Q1 2026 - Filings
- 2 months ago - Pelthos Therapeutics Announces First Quarter 2026 Financial Results - GlobeNewsWire